McKesson - MCK Stock Forecast, Price & News

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Robert W. Baird lifted their price target on McKesson from $386.00 to $400.00 and gave the company an "outperform" rating in a research note on Thursday, August 4th. Cowen upped their price target on McKesson to $384.00 in a research report on Tuesday, August 9th. Argus downgraded McKesson from a "buy" rating to a "hold" rating in a research note on Wednesday, July 6th. Credit Suisse Group upped their price target on McKesson from $377.00 to $385.00 and gave the stock an "outperform" rating in a research note on Monday, August 8th. Finally, UBS Group upped their price target on McKesson from $380.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, August 4th. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $337.62.

McKesson Stock Up 0.2 %

MCK Stock traded up $0.81 during trading on Tuesday, hitting $372.26. 95 shares of the company's stock traded hands, compared to its average volume of 953,794. The firm has a market capitalization of $53.50 billion, a P/E ratio of 39.27, a PEG ratio of 1.51 and a beta of 0.63. The business has a fifty day simple moving average of $328.45 and a two-hundred day simple moving average of $311.52. McKesson has a 1 year low of $193.89 and a 1 year high of $371.92.

McKesson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 3rd. Stockholders of record on Thursday, September 1st will be paid a dividend of $0.54 per share. This is an increase from McKesson's previous quarterly dividend of $0.47. This represents a $2.16 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend is Wednesday, August 31st. McKesson's payout ratio is presently 19.87%.

Insider Activity at McKesson

In other McKesson news, CFO Britt J. Vitalone sold 27,281 shares of the company's stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $333.16, for a total value of $9,088,937.96. Following the completion of the transaction, the chief financial officer now owns 13,693 shares in the company, valued at $4,561,959.88. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other McKesson news, CEO Brian S. Tyler sold 1,535 shares of the stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $305.20, for a total transaction of $468,482.00. Following the sale, the chief executive officer now directly owns 75,737 shares in the company, valued at approximately $23,114,932.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Britt J. Vitalone sold 27,281 shares of the stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $333.16, for a total transaction of $9,088,937.96. Following the completion of the sale, the chief financial officer now directly owns 13,693 shares in the company, valued at $4,561,959.88. The disclosure for this sale can be found here. Insiders sold 44,396 shares of company stock worth $14,471,365 over the last three months. Company insiders own 0.21% of the company's stock.